Researchers at the ibs.GRANADA are studying the use of a treatment that increases the survival of people with metastatic colorectal cancer.
A study directed by Dr. Beatríz González Astorga, researcher of the group A01-TECHNOLOGY APPLIED TO ONCOLOGY AND GENE THERAPY of the ibs.GRANADA at the San Cecilio Clinical University Hospital in Granada confirms that the TAS-102 treatment (oral antitumor agent) increases the survival of patients suffering from metastatic colorectal cancer.
The study, which was presented at the VII Congress of the Andalusian Society of Medical Oncology (SAOM), was carried out on 48 hospital patients, whose median age was 65 years. Median overall survival was 8,7 months in patients who received the treatment compared to the median 4,1 months in patients who had not.
Source: Granada Today. 05/11/2020.
Link to the news: https://www.granadahoy.com/granada/San-Cecilio-Granada-cancer_0_1516948624.html